PSD Bank Rhein-Ruhr eG

Suchergebnis - COMPASS PATHWAYS PLC (SPONS.ADRS) O.N.

Zeit	Titel
26.06 12:30	dpa-AFX: GNW-Adhoc: Compass Pathways appoints Lori Englebert as Chief Commercial Officer
08.05 12:45	dpa-AFX: GNW-Adhoc: Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
08.05 12:30	dpa-AFX: GNW-Adhoc: Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
02.05 12:30	dpa-AFX: GNW-Adhoc: Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
29.04 12:30	dpa-AFX: GNW-Adhoc: Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
28.03 13:00	dpa-AFX: GNW-Adhoc: Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
29.02 13:00	dpa-AFX: GNW-Adhoc: Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
16.01 14:00	dpa-AFX: GNW-Adhoc: Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
05.01 14:00	dpa-AFX: GNW-Adhoc: Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
19.12 22:05	dpa-AFX: GNW-Adhoc: Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
07.12 13:00	dpa-AFX: GNW-Adhoc: Compass Pathways appoints Teri Loxam as Chief Financial Officer
06.12 22:00	dpa-AFX: GNW-Adhoc: Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
15.11 10:00	dpa-AFX: GNW-Adhoc: Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
02.11 12:00	dpa-AFX: GNW-Adhoc: COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
26.10 14:00	dpa-AFX: GNW-Adhoc: COMPASS Pathways announces CFO transition
18.09 22:31	dpa-AFX: GNW-Adhoc: COMPASS Pathways appoints Daphne Karydas to its Board of Directors
06.09 10:00	dpa-AFX: GNW-Adhoc: COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
16.08 14:58	dpa-AFX: GNW-Adhoc: COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
03.08 13:00	dpa-AFX: GNW-Adhoc: COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
25.07 10:00	dpa-AFX: GNW-Adhoc: First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine